首页> 美国卫生研究院文献>Frontiers in Oncology >Combination of Decitabine and a Modified Regimen of Cisplatin Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure

【2h】

Combination of Decitabine and a Modified Regimen of Cisplatin Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure

机译：联合丁滨红细胞糖苷和地塞米松的改良方案：第二线治疗失败后复发或难治性弥漫性大B细胞淋巴瘤的潜在救助方案

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Frontiers in Oncology
作者
Junxia Hu; Xin Wang; Fei Chen; Mengjie Ding; Meng Dong; Wanqiu Yang; Meifeng Yin; Jingjing Wu; Lei Zhang; Xiaorui Fu; Zhenchang Sun; Ling Li; Xinhua Wang; Xin Li; Shuangshuang Guo; Dianbao Zhang; Xiaohui Lu; Qing Leng; Mingzhi Zhang; Linan Zhu; Xudong Zhang; Qingjiang Chen;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：Defitabine;化疗;弥漫性大B细胞淋巴瘤;改性DHAP方案;安全;

相似文献

外文文献
中文文献
专利

1. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma. [J] . Lignon J, Sibon D, Madelaine I, Clinical lymphoma, myeloma & leukemia . 2010,第4期

机译：利妥昔单抗，地塞米松，阿糖胞苷和奥沙利铂（R-DHAX）在复发/难治性B细胞非霍奇金淋巴瘤中是一种有效且安全的挽救方案。
2. Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. [J] . Oki Y, Ogura M, Kato H, Cancer science. . 2008,第1期

机译：在复发性或难治性B细胞非霍奇金淋巴瘤患者中，使用环磷酰胺，大剂量阿糖胞苷，地塞米松，依托泊苷和利妥昔单抗进行挽救方案的II期研究。
3. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. [J] . Mey UJ, Orlopp KS, Flieger D, Cancer investigation . 2006,第6期

机译：地塞米松，大剂量阿糖胞苷和顺铂联合利妥昔单抗作为挽救性治疗复发性或难治性侵袭性非霍奇金淋巴瘤的患者。
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Modified Irinotecan Plus Cisplatin and Dexamethasone (ICD) Combination Chemotherapy as Salvage Chemotherapy for Patients with Relapsed/Refractory Diffuse Large Cell Lymphoma [O] . Mojtaba Ghadiany, Mohammad Foratyazdi, Hossein Rahimi, 2014

机译：改良的伊立替康加顺铂和地塞米松（ICD）联合化学疗法作为挽救性化学疗法治疗复发/难治性弥漫性大细胞淋巴瘤患者
6. Combination of Decitabine and a Modified Regimen of Cisplatin, Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure [O] . Junxia Hu, Xin Wang, Fei Chen, 2021

机译：联合丁滨，红细胞，糖苷和地塞米松的改良方案：第二线治疗失败后复发或难治性弥漫性大B细胞淋巴瘤的潜在救助方案

Combination of Decitabine and a Modified Regimen of Cisplatin Cytarabine and Dexamethasone: A Potential Salvage Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Second-Line Treatment Failure

著录项

引文网络

相似文献

相关主题

期刊订阅